BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

MEDIAN Technologies to Present Study Results at the 2013 European Cancer Congress (ECC) in Amsterdam


9/27/2013 10:23:14 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SOPHIA ANTIPOLIS, France – September 27, 2013 – MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, today announced its participation in the European Cancer Congress (ECC), to be held next Sept. 27-Oct. 1, in Amsterdam, The Netherlands.

During the ECC — the premier European oncology conference, co-organized this year by the European Cancer Organization (ECCO), the European Society for Medical Oncology (ESMO) and the European Society for Radiotherapy and Oncology (ESTRO) — MEDIAN’s scientists will present the results of a study “Monitoring of Pulmonary Tumors in Computed Tomography: Thresholds for Volume-based Response Assessments and Target Lesions Selection” scheduled September, 29 9:30 to 12:00 in Hall 4 - http://eccamsterdam2013.ecco-org.eu/Scientific-Programme/Abstract-search.aspx (Abstract number 1150). Changes in lung tumor volume are emerging as a more sensitive imaging biomarker for disease evolution than uni-dimensional measurements of longest axial diameters. However, there are still missing scientific data to specify the magnitude of tumor volume changes that would allow classifying disease evolution and identifying if a patient responded to the therapy. This study proposes a solution for volume-based response assessments that provides thresholds for response, based on tumor volume, as well as a method for automatic identification of measurable lesions.

MEDIAN Technologies has also coauthored a poster publication presented by Saga University, Japan: “Evaluation of a Cloud-based Local Read Paradigm for Imaging Evaluations in Oncology Clinical Trials” scheduled September, 29th 9:30 to 12:00 in Hall 4 - http://eccamsterdam2013.ecco-org.eu/Scientific-Programme/Abstract-search.aspx (Abstract number 1153). The goal of the study is to evaluate a cloud-based paradigm implementing software solutions and services that standardize imaging evaluations among international investigator sites. The study was performed using MEDIAN’s Lesion Management Solutions (LMS) and MEDIAN’s Clinical Trial Imaging Services (CTIS).

MEDIAN’s scientific and business development teams will be present at Booth 3567 to discuss study results and to give demonstrations of MEDIAN’s LMS solutions.

About MEDIAN Technologies: MEDIAN Technologies provides advanced imaging solutions for diagnosing and monitoring cancer patients in clinical trials and in routine clinical practice. MEDIAN collaborates with institutes at the cutting edge of medical imaging, including the French National Institute for Computer Science and Control (INRIA), the University of Chicago, and the Swiss Federal Institute of Technology in Lausanne, Switzerland (EPFL). MEDIAN is present in the market through direct and indirect sales of its LMS solutions and through alliances with specialist cancer centers in Europe and the US. MEDIAN has a strategic partnership with Canon for the development of new technologies, and a strategic partnership with Quintiles to offer integrated imaging services for clinical trials to customers worldwide.

Based in Sophia Antipolis, France, MEDIAN was founded in 2002 by Fredrik Brag (CEO), Gérard Milhiet, and Arnaud Butzbach. The company has a staff of 45, over half of whom work in R&D, and has a US-based subsidiary in the Boston area.

MEDIAN has received the label "Innovative company" by OSEO and is listed on NYSE Euronext Paris' Alternext market (ISIN: FR0011049824, ticker: ALMDT).

For more information on MEDIAN, please visit: www.mediantechnologies.com

CONTACTS

MEDIAN Technologies Fredrik Brag, CEO + 33 492 906 582 fredrik.brag@mediantechnologies.com

Press

ALIZE RP Caroline Carmagnol + 33 664 189 959 caroline@alizerp.com

Christian Berg

+ 33 170 225 386 christian@alizerp.com

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES